Eli Lilly and Company (NYSE:LLY) Shares Purchased by Independent Advisor Alliance

Independent Advisor Alliance grew its stake in shares of Eli Lilly and Company (NYSE:LLYFree Report) by 1.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 32,269 shares of the company’s stock after purchasing an additional 544 shares during the quarter. Independent Advisor Alliance’s holdings in Eli Lilly and Company were worth $18,810,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Allworth Financial LP lifted its stake in shares of Eli Lilly and Company by 14.6% in the third quarter. Allworth Financial LP now owns 5,288 shares of the company’s stock worth $2,840,000 after acquiring an additional 672 shares in the last quarter. Knights of Columbus Asset Advisors LLC raised its position in shares of Eli Lilly and Company by 2.2% in the 3rd quarter. Knights of Columbus Asset Advisors LLC now owns 1,694 shares of the company’s stock valued at $910,000 after purchasing an additional 37 shares in the last quarter. Aspen Investment Management Inc purchased a new position in shares of Eli Lilly and Company during the 3rd quarter valued at approximately $317,000. Cadinha & Co. LLC grew its position in shares of Eli Lilly and Company by 3.1% during the third quarter. Cadinha & Co. LLC now owns 21,072 shares of the company’s stock worth $11,318,000 after buying an additional 630 shares in the last quarter. Finally, Triad Financial Advisors Inc. increased its stake in shares of Eli Lilly and Company by 6.5% in the third quarter. Triad Financial Advisors Inc. now owns 1,196 shares of the company’s stock worth $642,000 after buying an additional 73 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have commented on LLY. TheStreet upgraded shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a research note on Friday, March 8th. Truist Financial lifted their price target on Eli Lilly and Company from $850.00 to $892.00 and gave the stock a “buy” rating in a research note on Wednesday, May 1st. JPMorgan Chase & Co. boosted their price objective on Eli Lilly and Company from $850.00 to $900.00 and gave the company an “overweight” rating in a report on Wednesday, May 1st. Bank of America increased their target price on Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a “buy” rating in a report on Friday, March 1st. Finally, Barclays boosted their price target on Eli Lilly and Company from $680.00 to $810.00 and gave the company an “overweight” rating in a report on Wednesday, February 7th. Three analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $769.53.

View Our Latest Stock Analysis on LLY

Eli Lilly and Company Stock Performance

Shares of LLY traded down $1.12 during mid-day trading on Friday, reaching $770.00. 1,670,317 shares of the company’s stock traded hands, compared to its average volume of 2,877,174. The company has a debt-to-equity ratio of 1.90, a quick ratio of 1.03 and a current ratio of 1.35. The business’s 50-day moving average price is $760.66 and its 200-day moving average price is $685.22. The stock has a market capitalization of $731.82 billion, a P/E ratio of 113.40, a price-to-earnings-growth ratio of 1.52 and a beta of 0.37. Eli Lilly and Company has a 12 month low of $419.80 and a 12 month high of $800.78.

Eli Lilly and Company (NYSE:LLYGet Free Report) last announced its earnings results on Monday, May 6th. The company reported $2.58 earnings per share for the quarter, beating the consensus estimate of $2.53 by $0.05. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The firm had revenue of $8.77 billion for the quarter, compared to the consensus estimate of $8.94 billion. During the same quarter in the previous year, the business earned $1.62 EPS. The firm’s revenue for the quarter was up 26.0% on a year-over-year basis. Equities analysts predict that Eli Lilly and Company will post 13.82 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, June 10th. Investors of record on Thursday, May 16th will be issued a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 0.68%. The ex-dividend date is Wednesday, May 15th. Eli Lilly and Company’s payout ratio is currently 76.58%.

Eli Lilly and Company Company Profile

(Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

See Also

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLYFree Report).

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.